Similar to osteoporosis in patients without CKD, renal osteodystrophy in patients with low-grade CKD can be managed with bisphosphonates, calcium supplements, parathyroid hormones, RANKL-neutralizing antibodies, and selective estrogen receptor modulators. This evidence concerns the gene PTH and chronic kidney disease.